Form 8-K - Current report:
SEC Accession No. 0001193125-25-165462
Filing Date
2025-07-25
Accepted
2025-07-25 16:16:49
Documents
14
Period of Report
2025-07-23
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d71385d8k.htm   iXBRL 8-K 52750
2 EX-3.1 d71385dex31.htm EX-3.1 27638
3 EX-3.2 d71385dex32.htm EX-3.2 47719
  Complete submission text file 0001193125-25-165462.txt   274505

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA verv-20250723.xsd EX-101.SCH 2850
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE verv-20250723_lab.xml EX-101.LAB 18739
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE verv-20250723_pre.xml EX-101.PRE 11707
16 EXTRACTED XBRL INSTANCE DOCUMENT d71385d8k_htm.xml XML 3845
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

EIN.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 251151887
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)